Albert Hofmann and the Isolation of Psilocybin

In the mid-20th century, Swiss chemist Albert Hofmann inadvertently brought psilocybin to the attention of modern science. Known primarily for his discovery of lysergic acid diethylamide (LSD), Hofmann also played a pivotal role in isolating the active compounds in what were commonly called 'magic mushrooms'. This achievement in the 1950s bridged ancient indigenous practices with Western pharmacology. Today, psilocybin is strictly regulated—in South Africa, it is a Schedule 7 substance under the Medicines and Related Substances Act, making research complex—but its early history is rooted in rigorous scientific inquiry and international collaboration.

The Wasson Expedition and the Mazatec Context

The story of psilocybin’s isolation begins not in a Swiss laboratory, but in the mountains of Oaxaca, Mexico. In 1955, an American banker and amateur mycologist, R. Gordon Wasson, travelled to Mexico with his wife Valentina. There, they participated in a Mazatec ceremony involving the ritual use of psilocybin-containing mushrooms. The Mazatec people had used these fungi for generations as a sacrament for healing and divination. Wasson’s documentation of this practice in a 1957 *Life* magazine article brought international attention to the mushrooms, which he referred to by the Aztec term *teonanácatl* (often translated as 'flesh of the gods').

Recognising he lacked the expertise to chemically identify the active ingredients, Wasson sent biological specimens to French mycologist Roger Heim. Heim successfully cultivated some of these mushroom species in Paris, but isolating the precise psychoactive constituents proved difficult using the chemical techniques available at the time. To solve this, Heim sent samples to his colleague Albert Hofmann at Sandoz Pharmaceuticals in Basel, Switzerland.

Isolation and Synthesis at Sandoz

By the late 1950s, Hofmann was already a leading figure in alkaloid research, having synthesised LSD years earlier. When he received the dried mushroom samples from Heim in 1958, he faced a significant challenge: the active compounds were unstable and prone to degrading during extraction. Through a process of careful chemical fractionation—separating the mushroom's various components to isolate the active agent—Hofmann and his colleagues successfully extracted two primary alkaloids. They named these compounds psilocybin and psilocin.

Once isolated, Hofmann’s team determined the chemical structure of these molecules. They discovered that psilocybin was structurally similar to serotonin, a key neurotransmitter in the human brain. A major scientific milestone followed: Hofmann's team developed a method to synthetically produce psilocybin in the laboratory. This meant researchers no longer had to rely on rare, wild-harvested mushrooms to study its effects, allowing for standardised, reproducible scientific investigation. It is worth noting that Hofmann himself acknowledged that the isolation of the active ingredients did not diminish the cultural importance of the mushrooms themselves, recognising the indigenous knowledge that made the discovery possible.

Early Clinical Interest and Indocybin

With synthetic psilocybin available, Sandoz began distributing it to researchers under the trade name 'Indocybin' in the late 1950s. It was supplied to psychiatrists as an experimental tool to study the mechanisms of psychosis and consciousness. During this period, hundreds of academic papers were published exploring psilocybin’s psychological effects. This early clinical interest was completely legal and sponsored by a major pharmaceutical company, reflecting a time when psychedelics were viewed primarily as objects of scientific curiosity and therapeutic potential, rather than substances of abuse.

From Scientific Promise to Prohibition

The trajectory of psilocybin shifted dramatically in the late 1960s. As cultural and political attitudes toward psychedelics soured globally, regulatory bodies moved to restrict access. The United Nations Convention on Psychotropic Substances in 1971 classified psilocybin as a Schedule I substance, a category generally reserved for drugs with high abuse potential and no accepted medical use. This international treaty heavily influenced domestic drug policies worldwide.

In South Africa, psilocybin is currently listed as a Schedule 7 substance under the Medicines and Related Substances Act, placing it in the highest restriction category alongside drugs like heroin. This legal status effectively paused the type of research that Hofmann’s isolation had initiated for several decades. Today, however, institutions globally are re-examining psilocybin’s therapeutic potential in clinical trials, reconnecting modern neuroscience with the chemical history that began in Hofmann’s laboratory.